Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : J&J COVID-19 shot gets better boost from Moderna or Pfizer in NIH study

10/13/2021 | 04:57pm EST

Oct 13 (Reuters) - People who got Johnson & Johnson Inc’s COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer Inc /BioNTech SE or Moderna Inc, a study run by the National Institutes of Health showed on Wednesday.

The study, which is preliminary and hasn't been peer reviewed, is the latest challenge to J&J's efforts to use its COVID-19 vaccine as a booster in the United States.

The study, which included more than 450 adults who received initial shots from Pfizer, Moderna, or Johnson & Johnson, showed that "mixing and matching" booster shots of different types is safe in adults. Moderna's and Pfizer's vaccines are based on messenger RNA while J&J's uses viral vector technology.

It comes as an advisory group to the U.S. Food and Drug Administration is preparing to meet later this week to discuss the merits of a booster shot for Moderna and J&J vaccines.

FDA officials on Wednesday said J&J's regulatory submission for its planned booster raised red flags including small sample sizes and data based on tests that had not been validated.

U.S. health officials have been under pressure to offer advice on booster doses of the J&J and Moderna COVID-19 vaccines after the White House announced in August it planned to roll out boosters beginning last month for most adults.

The NIH study contrasted the safety and immune response of volunteers who were boosted with the same type of shot they had been given for their initial vaccination with those who received a different type of shot as a booster.

Mixing and matching doses for a booster produced similar side effects to those seen in primary inoculations and raised no significant safety concerns, the study said.

The study of the three COVID-19 vaccines currently authorized in the United States showed that using different types of shots as boosters generally appeared to produce a comparable or higher antibody response than using the same type.

The trial took place in 10 U.S. cities and used a total of nine combinations of initial shots and boosters.

Mixing booster doses "may offer immunological advantages to optimize the breadth and longevity of protection achieved with currently available vaccines," researchers wrote in the study. (Reporting by Amruta Khandekar and Carl O'DOnnell; Additional reporting by Julie Steenhuysen; Editing by Maju Samuel, Jonathan Oatis and Diane Craft)

© Reuters 2021
All news about MODERNA, INC.
01:53pModerna Shares Drop After US Court Rejects Appeal of Arbutus Patents
01:33pEquities Led Higher Midday by Energy, Financials Following BioNTech CEO Comment on Vacc..
01:24pMIDDAY REPORT : US Stocks Led Higher by Energy, Financials Following BionTech CEO Comment ..
12:50pCuba to upgrade homegrown COVID-19 vaccine to confront Omicron
05:40aOil Markets See High Volatility Week with Slight Rally in Asia, OANDA Analyst Says
04:06aModerna CEO Says Vaccines Likely Less Effective Against Omicron
03:55aCOVID comeback caps a November to remember in markets
01:21aGlobal markets dip as Moderna chief sounds alarm on Omicron
01:07aOmicron Variant Was in Western Europe Days Before First Identified in Southern Africa
12:48aAsian shares bounce sharply from year low but Omicron, Fed in focus
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 449 M - -
Net income 2021 11 169 M - -
Net cash 2021 12 344 M - -
P/E ratio 2021 13,4x
Yield 2021 -
Capitalization 143 B 143 B -
EV / Sales 2021 7,48x
EV / Sales 2022 5,84x
Nbr of Employees 1 300
Free-Float 90,5%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 18
Last Close Price 352,43 $
Average target price 272,53 $
Spread / Average Target -22,7%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.237.35%142 893
LONZA GROUP AG30.63%59 859
SEAGEN INC.-8.64%29 257
CELLTRION, INC.-42.34%23 827